Number of the records: 1
Tumour-initiating cells vs. cancer "stem" cells and CD133: What's in the name?
- 1.
SYSNO ASEP 0096517 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Ostatní články Title Tumour-initiating cells vs. cancer "stem" cells and CD133: What's in the name? Title Buňky iniciující nádory či rakovinné "kmenové" buňky a CD133: co je po jméně? Author(s) Neužil, Jiří (UMG-J)
Stantic, M. (AU)
Zobalová, Renata (UMG-J)
Chladová, Jaromíra (UMG-J)
Wang, X. F. (AU)
Procházka, L. (CZ)
Dong, L. (AU)
Anděra, Ladislav (UMG-J) RID
Ralph, S.J. (AU)Source Title Biochemical and Biophysical Research Communications. - : Elsevier - ISSN 0006-291X
Roč. 255, č. 4 (2007), s. 855-859Number of pages 5 s. Language eng - English Country US - United States Keywords tumour-initiating cells ; CD133 ; resistance to treatment Subject RIV EB - Genetics ; Molecular Biology CEZ AV0Z50520514 - UMG-J (2005-2011) AV0Z50520701 - BTO-N (2007-2013) Annotation Recent evidence suggests that a subset of cells within a tumour have "stem-like" characteristics. These tumour-initiating cells, distinct from non-malignant stem cells, show low proliferative rates, high self-renewing capacity, propensity to differentiate into actively proliferating tumour cells, resistance to chemotherapy or radiation, and they are often characterised by elevated expression of the stem cell surface marker CD133. Understanding the molecular biology of the CD133+ cancer cells is now essential for developing more effective cancer treatments. These may include drugs targeting organelles, such as mitochondria or lysosomes, using highly efficient and selective inducers of apoptosis. Alternatively, agents or treatment regimens that enhance sensitivity of these therapy-resistant "tumour stem cells" to the current or emerging anti-tumour drugs would be of interest as well. Workplace Institute of Molecular Genetics Contact Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Year of Publishing 2008
Number of the records: 1